Showing 811-820 of 1501 results for "".
- Industry Vet Crystal Muilenburg Joins Elevai’s Board of Directorshttps://modernaesthetics.com/news/industry-vet-crystal-muilenburg-joins-elevais-board-of-directors/2473357/Crystal Muilenburg is the newest member of Elevai’s Board of Directors. A former Evolus and Allergan executive, Muilenburg will play a key role in supporting the Elevai management team as it commercializes Elevai’s flagship exosome product line while driving t
- Study: Jeuveau “Extra-Strength” Dose Shows Lasting Resultshttps://modernaesthetics.com/news/evolus-to-present-phase-2-interim-data-from-jeuveau-extra-strength-dose-for-extended-duration-study-at-2023-imcas-world-congress/2473346/Evolus' Jeuveau Extra-Strength achieved one-point improvement on the Glabellar Lines Scale with the duration of effect lasting 26 weeks, representing a prolonged 6-month performance, the Company reports. The extra-strength glabellar line study is a multicenter, double
- Endo Pulls Qwo from Markethttps://modernaesthetics.com/news/endo-pulls-qwo-from-market/2473339/Endo International plc is ceasing the production and sale of Endo Aesthetics' Qwo (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloratio
- Galderma Celebrates Self-Expression at Miami Art Week 2022https://modernaesthetics.com/news/galderma-celebrates-self-expression-at-miami-art-week-2022/2473335/Galderma is the exclusive aesthetic injectables sponsor of the 21st annual SCOPE Miami Beach 2022 art show. Galderma will be highlighting its aesthetics portfolio – Restylane, Dysport (abobotulinumtoxinA) and Sculptra – and hosting a variety of
- Rebrand Alert: Crown's ProGen PRP Advantage Is Now ProGen PRP Eclipsehttps://modernaesthetics.com/news/rebrand-alert-crowns-progen-prp-advantage-is-now-progen-prp-eclipse/2473324/Crown Aesthetics completed the rebranding of ProGen PRP Advantage, now renamed ProGen PRP Eclipse. ProGen PRP Eclipse is a one-spin system that features 15 mL and 30 mL tubes, yielding 7-15 mL of Platelet Rich Plasma. "Crown's commitment to best-in-class service
- Evio Beauty Supports Domestic Violence Survivorshttps://modernaesthetics.com/news/evio-beauty-supports-domestic-violence-survivors/2473319/Evio Beauty is teaming up with FreeFrom, a US-based non-profit organization dedicated to helping survivors of intimate partner violence achieve economic justice and long-term financial stability. Evio will donate one dollar from every sale of their Lip Serum (in any shade) to FreeFrom.
- U.S. FDA Clears EndyMed’s Pure Laser Hair Removal Devicehttps://modernaesthetics.com/news/us-fda-clears-endymeds-pure-laser-hair-removal-device/2473318/The US Food and Drug Administration has cleared Endymed Ltd’s Pure Laser hair removal device for the marketing and sales. The Pure Laser was developed in the Company's labs by its subsidiary Endymed Medical Ltd. The Company intends to commence marketing in the US th
- New Indications for SkinPen in the EU and UKhttps://modernaesthetics.com/news/new-indications-for-skinpen-in-the-eu-and-uk/2473310/Crown Aesthetics’ SkinPen Precision scored three new approved indications in the EU and UK. The new&
- Galderma Gives Back: Brand Partners with NBCF to Launch Campaign Elevating Skin Stories of Breast Cancer Survivorshttps://modernaesthetics.com/news/galderma-gives-back-brand-partners-with-nbcf-to-launch-campaign-elevating-skin-stories-of-breast-cancer-survivors/2473307/Galderma is continuing its partnership with National Breast Cancer Foundation Inc. (NBCF) with a new campaign that elevates the skin stories of breast cancer survivors. Galderma is featuring the personal stories and treatment journeys of breast cancer survivors who receivedRestylan
- New Research Highlights the Efficacy and Safety Profile of Revance's DAXXIFYhttps://modernaesthetics.com/news/new-research-highlights-the-efficacy-and-safety-profile-of-revances-daxxify/2473304/Two new studies highlight the efficacy and safety profile of Revance Therapeutics, Inc.’s newly approved DAXXIFY (DaxibotulinumtoxinA-lanm). Glabellar injection of DAXXIFY showed a positive effect on eyebrow position, with a modest reduction in forehead muscle activity in&nbs